Evaluating Imeglimin as a Novel Therapeutic Action Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
INTRODUCTION/OBJECTIVE Imeglimin is the first agent of the novel glimin class that targets mitochondrial dysfunction, a key pathophysiological mechanism underlying type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of imeglimin in patients with T2DM. ME...